Despite an increasing number of patients with type 2 diabetes (T2D) in the older population, clinical evidence for different therapeutic strategies in the elderly is poor. Therefore, we used the REALI pooled database, which includes a large number of studies conducted in different European countries to evaluate the impact of initiating insulin glargine 300 U/mL (Gla-300) in older patients with T2D. Pooled efficacy and safety analyses of data from three interventional and five observational studies (pooled treated patients, n=5806) were performed on three age groups of patients: <65 (n=2874), 65 to <75 (n=1819), and ≥75 years old (y.o.) (n=1105); age data were missing for 8 patients. The proportion of females, median diabetes duration at baseline and prior use of insulin glargine 100 U/mL increased with age, whereas mean body weight and mean eGFR at baseline decreased with age. Diabetes complications and/or concomitant cardiovascular diseases and risk factors were more frequent in patients ≥75 y.o. Mean (SD) HbA1c (%) at baseline was 8.61 (1.08), 8.42 (0.95), and 8.39 (0.94) in the <65, 65 to <75, and ≥75 y.o. age groups, respectively. The least square mean [95% confidence interval] HbA1c change from baseline to Week 24 of Gla-300 treatment was -0.87 [-0.93; -0.82], -0.83 [-0.89; -0.77] and -0.77 [-0.88; -0.67], respectively. Similar proportions of patients reached the HbA1c <7% and <7.5% goals at Week 24 across the three age groups, with no notable differences between the age groups in incidence of severe (0.7%, 1.2% and 1.2% respectively) and nocturnal (3.1%, 3.6% and 1.7% respectively) hypoglycemia, or mean change in body weight and Gla-300 dose (U/Kg/day) from baseline to Week 24. Gla-300 was well tolerated across all age groups. This pooled data analysis shows that initiation of treatment with insulin glargine 300 U/mL in older (≥ 75 y.o) patients with T2D has a similar efficacy and safety profile as in younger adults, and extends the evidence on treatment of older patients.

Disclosure

R.C. Bonadonna: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Sanofi-Aventis. Speaker's Bureau; Self; Eli Lilly and Company, Sanofi-Aventis. D. Mauricio: Advisory Panel; Self; Merck Sharp & Dohme Corp., Sanofi. Speaker's Bureau; Self; Almirall, S.A., Boehringer Ingelheim International GmbH, Lilly Diabetes, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Urgo Medical. D. Müller-Wieland: Advisory Panel; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi-Aventis Deutschland GmbH. N. Freemantle: Advisory Panel; Self; Sanofi. Research Support; Self; Akcea Therapeutics, Allergan, AstraZeneca, Ipsen Biopharmaceuticals, Inc., Sanofi, Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Sanofi. G. Bigot: None. C. Mauquoi: None. A. Ciocca: Employee; Self; Sanofi. M. Bonnemaire: Employee; Self; Sanofi. P. Gourdy: Advisory Panel; Self; AstraZeneca. Board Member; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis, Servier. Speaker's Bureau; Self; Abbott, Amgen Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis, Servier.

Funding

Sanofi

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.